Chabiotech Co

Chabiotech Co OCF Margin

The Operating Cash Flow Margin of Chabiotech Co (085660.KQ) as of Nov 1, 2026 is -5.72 %. In the previous year, Operating Cash Flow Margin was -4.74 % — a change of 20.61% (lower).

OCF Margin

-5.72 %

YoY

20.61%

Last updated:

Operating Cash Flow Margin of Chabiotech Co is 2025 -5.72 % . Operating Cash Flow Margin of Chabiotech Co was 2024 -4.74 % . It decreases by 20.61% lower compared to the previous year.

The Chabiotech Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
15.43 KRW
Jan 1, 2019
4.72 KRW
Jan 1, 2020
7.07 KRW
Jan 1, 2021
3.06 KRW
Jan 1, 2022
-2.44 KRW
Jan 1, 2023
1.21 KRW
Jan 1, 2024
-4.74 KRW
Jan 1, 2025
-5.72 KRW
The Chabiotech Co OCF Margin history
YEAROCF MarginYoY
-5.72 %+20.61%
-4.74 %-492.89%
1.21 %-149.40%
-2.44 %-179.94%
3.06 %-56.78%
7.07 %+49.76%
4.72 %-69.40%
15.43 %+436.31%
2.88 %+14.44%
2.51 %-84.00%
15.71 %-2,212.76%
-0.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Chabiotech Co Stock analysis

What does Chabiotech Co do? Cha Biotech Co., Ltd. generates revenue through its bio segment, which provides medical services, develops stem cell and cell therapy products, produces cosmetics and cosmetic raw materials, distributes medical devices, and offers cord blood storage and health care services. The optical segment manufactures optical lenses, optical modules, and other parts for mobile phone cameras. The company serves healthcare providers, medical device distributors, and consumers seeking cosmetic and health services. Its bio segment targets medical and wellness markets, while the optical segment caters to mobile phone manufacturers and component suppliers. The company's products include stem cell therapy solutions, cosmetic raw materials, medical devices, and optical components. It operates through two main segments: bio and optical, with the bio segment focusing on healthcare and wellness services, and the optical segment on manufacturing optical parts for mobile devices. The bio segment's cord blood storage services are a key offering for health-conscious consumers, while the optical segment supplies components to mobile phone camera manufacturers. Cha Biotech's revenue streams come from medical service provision, product development in cell therapy, cosmetic production, medical device distribution, cord blood storage, and optical component manufacturing. The company serves healthcare institutions, cosmetic brands, medical device companies, and mobile phone manufacturers. Its bio segment's health care services and optical segment's mobile phone camera parts are central to its business model. Chabiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chabiotech Co stock

Operating Cash Flow Margin of Chabiotech Co is -5.72 % in 2025.

Operating Cash Flow Margin of Chabiotech Co changed from -4.74 % to -5.72 %, representing a 20.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Chabiotech Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Chabiotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Chabiotech Co

All Key Metrics — Chabiotech Co